文献速递脑血管病

达比加群与阿司匹林在伴卵圆孔未闭的隐源性卒中患者中的比较:RE-SPECT ESUS结果

Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
PubMed 文献 · Stroke · 2021-01-28

RE-SPECT ESUS研究纳入5388例隐源性卒中患者,其中680例(12.6%)存在卵圆孔未闭(PFO)。在伴或不伴PFO的患者中,达比加群与阿司匹林对复发性卒中的风险相似(交互作用P=0.8290)。荟萃分析显示,在PFO患者中抗凝与抗血小板治疗对缺血性卒中的差异无统计学意义(OR 0.70,95%CI 0.43-1.14)。

要点

  • 在伴PFO的ESUS患者中,达比加群与阿司匹林预防复发性卒中的效果相似。
  • 荟萃分析未发现抗凝优于抗血小板治疗伴PFO的ESUS患者。
  • 目前证据不足以推荐对伴PFO的ESUS患者优先使用抗凝治疗。

核心结论

  • 证据不足以推荐对伴卵圆孔未闭的隐源性卒中患者优先使用抗凝而非抗血小板治疗,需更多数据指导抗栓治疗。

研究设计与样本

  • RE-SPECT ESUS随机双盲试验的事后分析,纳入5388例隐源性卒中患者,比较达比加群(150/110 mg 每日两次)与阿司匹林(100 mg 每日一次)。

主要发现

  • 5388例患者中680例(12.6%)存在卵圆孔未闭。
  • 伴或不伴PFO的患者中,达比加群与阿司匹林对复发性卒中的风险相似(交互作用P=0.8290)。
  • 荟萃分析显示,在PFO患者中抗凝与抗血小板治疗对缺血性卒中的差异无统计学意义(OR 0.70,95%CI 0.43-1.14)。

临床怎么用

  • 对于伴PFO的隐源性卒中患者,在未进行介入封堵时,现有证据不支持常规优先选择抗凝治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Patent foramen ovale (PFO) may increase the risk of embolic stroke of undetermined source (ESUS). Guidelines suggest anticoagulation may be more effective than antiplatelets in preventing stroke in patients with ESUS and PFO when interventional closure is not performed. METHODS: Patients with ESUS randomized to dabigatran (150/110 mg BID) or aspirin (100 mg QD) from the RE-SPECT ESUS study (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) were included. The rate of recurrent stroke (primary end point) and ischemic stroke was reported for patients with and without baseline PFO. A meta-analysis comparing the effects of anticoagulant and antiplatelet therapy on ischemic stroke in patients with PFO was updated to include RE-SPECT ESUS. RESULTS: PFO was present in 680 of 5388 (12.6%) patients with documented PFO status. The risk of recurrent stroke with dabigatran versus aspirin was similar in patients with and without PFO (P for interaction, 0.8290). In patients with PFO, the meta-analysis found no statistically significant difference between anticoagulant and antiplatelet therapy (odds ratio, 0.70 [95% CI, 0.43-1.14]) for ischemic stroke. CONCLUSIONS: There is insufficient evidence to recommend anticoagulation over antiplatelet therapy for patients with ESUS and a PFO. More data are needed to guide antithrombotic therapy in this population. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02239120.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Diener HC, Chutinet A, Easton JD, et al. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. Stroke. 2021. PMID: 33504190. doi:10.1161/STROKEAHA.120.031237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。